GLP-1 Receptor Agonists. How The Study Was Built. The investigators used the TriNetX US Collaborative Network and identified 841,831 eligible adult women with breast cancer across 68 healthcare organizations.
Introduction and Objective: GLP-1 receptor agonists (GLP-1 RAs) may reshape obesity management & diabetes prevention. However, there is scant evidence about global populations who may benefit from them. Here we evaluate eligibility for GLP-1 RAs across 91 countries.
GLP-1 receptor agonists have emerged as biologically plausible modulators of reward circuitry and addictive behavior. Preclinical data are robust and consistent across substances, while human evidence provides encouraging but non-causal signals.
Across world regions, eligibility for GLP-1 receptor agonists for weight management varied substantially, with the highest eligibility seen in Europe and North America and in the Pacific Islands (42.8 and 41.0 percent, respectively).
Furthermore, visual representations like the one above help us fully grasp the concept of Complexities In Diagnosing Patients Eligible For Glp-1 Receptor Agonists.
Mounjaro (tirzepatide) is the first and only, once-weekly approved single-molecule GIP and GLP-1 receptor agonist that helps lower A1C for adults with type 2 diabetes.
Recent advances in GLP-1 receptor agonists: focus on safety and efficacy.
In clinical trials, GLP-1RAs were well tolerated and effective at helping people prevent weight regain, and may be a good option for long-term weight control and lowering patients chances of serious health problems.
